ArticleJournal of clinical medicine2023
Heart Failure Pharmacological Management: Gaps and Current Perspectives.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Identification and verification of biomarkers associated with integrated stress response in heart failure.Scientific reports · 2026Article
- Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology.Cardiovascular drugs and therapy · 2026Observational
- Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Observational
- Implications of Oxidative Stress in the Pathophysiological Pathways of Heart Failure.International journal of molecular sciences · 2025Review
- Review
- Review
- Breaking new ground in heart failure management: novel therapies and future frontiers.Frontiers in cardiovascular medicine · 2025Review
- The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and Angiotensin Receptor-neprylisin Inhibitors in Acute Heart Failure (PENTA-HF).Current vascular pharmacology · 2025Observational
- Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Different Scenarios of Heart Failure: An Overview of the Current Literature.International journal of molecular sciences · 2024Review
- Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Observational
- Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Review
- Review
- Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2024Review
- The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum.Journal of clinical medicine · 2024Article
- Prognostic Assessment of HLM Score in Heart Failure Due to Ischemic Heart Disease: A Pilot Study.Journal of clinical medicine · 2024Article
- Heart failure 'the cancer of the heart': the prognostic role of the HLM score.ESC heart failure · 2024Observational
- Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights.International journal of molecular sciences · 2024Review
- Telemedicine: an Effective and Low-Cost Lesson From the COVID-19 Pandemic for the Management of Heart Failure Patients.Current heart failure reports · 2023Review
- Clinical Usefulness of Speckle-Tracking Echocardiography in Patients with Heart Failure with Preserved Ejection Fraction.Diagnostics (Basel, Switzerland) · 2023Review
- SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proper therapeutic management of patients with heart failure (HF) is a major challenge for cardiologists. Current guidelines indicate to start therapy with angiotensin converting enzyme inhibitors/angiotensin receptor neprilysin inhibitors (ACEi/ARNI), beta blockers (BB), mineralocorticoid receptor antagonists (MRAs) and sodium glucose cotransporter 2 inhibitors (SGLT2i) to reduce the risk of death and hospitalization due to HF. However, certain aspects still need to be defined. Current guidelines propose therapeutic algorithms based on left ventricular ejection fraction values and clinical presentations. However, these last do not always reflect the precise hemodynamic status of patients and pathophysiological mechanisms involved, particularly in the acute setting. Even in the field of chronic management there are still some critical points to discuss. The guidelines do not specify which of the four pillar drugs to start first, nor at what dosage. Some authors suggest starting with SGLT2i and BB, others with ACEi or ARNI, while one of the most recent approach proposes to start with all four drugs together at low doses. The aim of this review is to revise current gaps and perspectives regarding pharmacological therapy management in HF patients, in both the acute and chronic phase.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.